Biblio Discovery — Demo Discovery Service

11 results for "Martin Lagging"

Showing 1–11 · 0.37 seconds · RSS

  1. Journal Article Full text

    No need to discontinue hepatitis C virus therapy at the time of liver transplantation

    Catarina Skoglund; Martin Lagging; Maria Castedal

    PLOS ONE, Vol. 14 No. 2 · 2019 · English · PLOS Scopus

    Objectives: Direct antiviral agents (DAA) has dramatically improved the therapy outcome of hepatitis C-virus (HCV) infection, both on the waiting-list and post liver transplantation (LT). DAA are generally well-tolerated in patients with mild to moderate liver and kidney failure, but some DAAs are…

  2. Journal Article Full text

    The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection

    Jesper Waldenström; Kristina Nyström; Staffan Nilsson et al.

    PLOS ONE, Vol. 15 No. 8 · 2020 · English · PLOS Scopus

    Background and objectives: The hydroxylation to 25-hydroxy vitamin D (25(OH)D) occurs in the liver and the impact of liver disease on vitamin D is unclear. This study evaluated the relationship between vitamin D concentrations and hepatic histopathology, seasonality and patient characteristics in…

  3. Journal Article Full text

    Impact of IL28B -Related Single Nucleotide Polymorphisms on Liver Transient Elastography in Chronic Hepatitis C Infection

    Magdalena Ydreborg; Johan Westin; Karolina Rembeck et al.

    PLoS ONE, Vol. 8 No. 11 · 2013 · English · PLOS Scopus

    Background and Aims: Recently, several genome-wide association studies have revealed that single nucleotide polymorphisms (SNPs) in proximity to IL28B predict spontaneous clearance of hepatitis C virus (HCV) infection as well as outcome following pegylated interferon and ribavirin therapy among…

  4. Journal Article Full text

    Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens

    Aparna Vasanthakumar; Justin W. Davis; Manal Abunimeh et al.

    PLOS ONE, Vol. 13 No. 5 · 2018 · English · PLOS Scopus

    Background: Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV). Patients with reduced ITPase activity showed…

  5. Journal Article Full text

    Impact of IL28B -Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3

    Karolina Rembeck; Åsa Alsiö; Peer Brehm Christensen et al.

    PLoS ONE, Vol. 7 No. 1 · 2012 · English · PLOS Scopus

    Background and Aims: Recently, several genome-wide association studies have revealed that single nucleotide polymorphisms (SNPs) in proximity to IL28B predict spontaneous clearance of HCV infection as well as outcome following peginterferon and ribavirin therapy among HCV genotype 1 infected…

  6. Journal Article Full text

    A Novel Fibrosis Index Comprising a Non-Cholesterol Sterol Accurately Predicts HCV-Related Liver Cirrhosis

    Magdalena Ydreborg; Vera Lisovskaja; Martin Lagging et al.

    PLoS ONE, Vol. 9 No. 4 · 2014 · English · PLOS Scopus

    Diagnosis of liver cirrhosis is essential in the management of chronic hepatitis C virus (HCV) infection. Liver biopsy is invasive and thus entails a risk of complications as well as a potential risk of sampling error. Therefore, non-invasive diagnostic tools are preferential. The aim of the…

  7. Journal Article Full text

    Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3

    Åsa Alsiö; Karolina Rembeck; Galia Askarieh et al.

    PLoS ONE, Vol. 7 No. 5 · 2012 · English · PLOS Scopus

    Background and Aims: Having a body mass index above or equal to 30 kg/m2 in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the mechanisms whereby obesity reduces the efficacy of therapy…

  8. Journal Article Full text

    Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections—A Scandinavian real-life study

    Olav Dalgard; Ola Weiland; Geir Noraberg et al.

    PLOS ONE, Vol. 12 No. 7 · 2017 · English · PLOS Scopus

    Background and aims: Chronic hepatitis C virus (HCV) genotype 3 infection with advanced liver disease has emerged as the most challenging to treat. We retrospectively assessed the treatment outcome of sofosbuvir (SOF) based regimes for treatment of HCV genotype 3 infections in a real life setting…

  9. Journal Article Full text

    Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection

    Jonas Söderholm; Jesper Waldenström; Galia Askarieh et al.

    PLoS ONE, Vol. 8 No. 2 · 2013 · English · PLOS Scopus

    Background: Interferon and ribavirin therapy for chronic hepatitis C virus (HCV) infection yields sustained virological response (SVR) rates of 50–80%. Several factors such as non-1 genotype, beneficial IL28B genetic variants, low baseline IP-10, and the functionality of HCV-specific T cells…

  10. Journal Article Full text

    Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B -Related Single Nucleotide Polymorphisms

    Martin Lagging; Galia Askarieh; Francesco Negro et al.

    PLoS ONE, Vol. 6 No. 2 · 2011 · English · PLOS Scopus

    Background: High baseline levels of IP-10 predict a slower first phase decline in HCV RNA and a poor outcome following interferon/ribavirin therapy in patients with chronic hepatitis C. Several recent studies report that single nucleotide polymorphisms (SNPs) adjacent to IL28B predict spontaneous…